Stockscreener 앱 받기
75.11
1.03%
-0.78
시간 외 거래:
75.99
0.88
+1.17%
전일 마감가:
$75.89
열려 있는:
$75.95
하루 거래량:
1.61M
Relative Volume:
2.58
시가총액:
$3.35B
수익:
$156.12M
순이익/손실:
$-395.33M
주가수익비율:
-7.239
EPS:
-10.3758
순현금흐름:
$-292.33M
1주 성능:
-3.06%
1개월 성능:
+10.67%
6개월 성능:
+64.17%
1년 성능:
+93.66%
1일 변동 폭
$74.12
$78.86
1주일 범위
$73.46
$79.19
52주 변동 폭
$36.98
$118.84
Grail Inc Stock (GRAL) Company Profile
명칭
Grail Inc
전화
(833) 694-2553
주소
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, NTRA, IQV, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
75.11 | 3.40B | 156.12M | -395.33M | -292.33M | -10.38 |
TMO
Thermo Fisher Scientific Inc
|
648.43 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
208.36 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
345.34 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
268.82 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
153.69 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Mizuho | Neutral |
| 2026-03-18 | 업그레이드 | TD Cowen | Hold → Buy |
| 2026-02-19 | 개시 | TD Cowen | Hold |
| 2026-02-17 | 개시 | Robert W. Baird | Outperform |
| 2025-12-02 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-11-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-04-21 | 개시 | Canaccord Genuity | Buy |
| 2024-11-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-10-17 | 개시 | Guggenheim | Neutral |
모두보기
Grail Inc 주식(GRAL)의 최신 뉴스
Analysts Offer Insights on NA Companies: Chime Financial, Inc. Class A (CHYM), GRAIL Inc (GRAL) and ServiceTitan, Inc. Class A (TTAN) - The Globe and Mail
UBS Initiates Coverage of Grail With Buy Rating, Caris, Tempus, Twist With Neutral - GenomeWeb
GRAIL (GRAL) Institutional Ownership 2026 $GRAL - MarketBeat
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone - Stocktwits
Grail CFO Sells 7,900 Shares Amid Strong Stock Performance - intellectia.ai
Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000 - Yahoo Finance
GRAL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test - Yahoo Finance
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Have Insiders Sold GRAIL Shares Recently? - simplywall.st
Grail CFO Aaron Freidin sells $671,579 in company stock By Investing.com - Investing.com South Africa
Grail CFO Aaron Freidin sells $671,579 in company stock - Investing.com
Grail CEO Joshua Ofman sells $425,098 in company stock - Investing.com
GRAIL CFO sells 7,900 shares at $85.01 avg - Stock Titan
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference - TradingView
GRAIL (NASDAQ: GRAL) insider Joshua Ofman plans to sell 10,000 shares - Stock Titan
GRAIL2026 Funding Rounds & List of Investors - Tracxn
Biotech Frenzy Sends GRAIL Soaring Ahead of FDA Showdown - TipRanks
Investigation announced for Long-Term Investors in shares of GRAIL, Inc. (NASDAQ: GRAL) over potential Wrongdoing - openPR.com
GRAIL (GRAL) Earnings Report: Profit Per Share Surpasses Its Benchmark in the Current Update; Post-Report: The Market Price Advances 6.19% in Latest TradingGross Profit Margin - dars.gov.et
Grail Stock Rockets Back As Traders Buy The Dip - TipRanks
GRAIL (GRAL), What Is Behind The Fresh Attention On The Stock? - simplywall.st
Why Silver Grail Resources Ltd stock is skyrocketing today - Wealth Awesome
Whoop expands Advanced Labs to non-members, adds Grail’s multi-cancer detection test to lineup - Fierce Healthcare
Russell Investments Group Ltd. Has $1.94 Million Holdings in GRAIL, Inc. $GRAL - MarketBeat
How (GRAL) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
GRAL Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Season Review - Vinanet
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting - MarketBeat
GRAL|Grail Inc|Price:68.180|Chg%:-0.760 - TradingKey
Farallon group discloses 9.6% GRAIL, Inc. (GRAL) holding in Schedule 13G/A - Stock Titan
GRAIL Q2 2026 Earnings: EPS Beats Estimates by 5.37% Amid Muted Stock ReactionEarnings Acceleration Picks - Vinanet
GRAIL Inc. (GRAL) Edges Lower 0.84% as Shares Hold Above $64.94 SupportValue Area Low - Vinanet
GRAIL, Inc. (NASDAQ:GRAL) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Bank of America Corp DE Purchases 205,611 Shares of GRAIL, Inc. $GRAL - MarketBeat
GRAIL: Looking Beyond The NHS-Galleri Headline (NASDAQ:GRAL) - Seeking Alpha
GRAIL (NASDAQ:GRAL) Stock Price Down 6.3%What's Next? - MarketBeat
Cancer Detection Firm Nears FDA Breakthrough Blood-Test Review - Streetwise Reports
GRAIL Galleri Test Heads to FDA Panel for Multi-Cancer Screening Review - Streetwise Reports
GRAIL INC : PIPER SANDLER RAISES TARGET PRICE TO $74 FROM $56 - webull.com
FDA panel to review GRAIL’s Galleri multi-cancer blood test in September - Mugglehead Investment Magazine
GRAIL (NASDAQ:GRAL) Trading Up 7.6%Time to Buy? - marketbeat.com
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test - Benzinga
FDA panel to weigh Grail’s Galleri test - STAT
GRAIL’s Galleri becomes first multi-cancer detection test headed to US FDA advisory panel - AllSci
Renaissance Technologies LLC Sells 30,100 Shares of GRAIL, Inc. $GRAL - MarketBeat
Illumina Seeks Court Approval of GRAIL Settlement - The Globe and Mail
GRAIL Inc Revenue Breakdown – LSX:A40F8M - TradingView
Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date? - Yahoo Finance
US FDA to hold advisory meeting to review Grail’s multi-cancer test - WTVB
US FDA to hold advisory meeting to review Grail's multi-cancer test - Reuters
FDA to hold adcomm for Grail cancer test that failed in large, randomized trial - Endpoints News
Grail Inc (GRAL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Grail Inc 주식 (GRAL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Freidin Aaron | Chief Financial Officer |
Aug 27 '26 |
Sale |
85.01 |
7,900 |
671,579 |
253,083 |
0.00%
자본화:
|
볼륨(24시간):